Treatment Efficacy Score a Better Way to Predict Long-Term Survival in Breast Cancer Trials
Yale Cancer Center/Smilow Cancer HospitalIn a study led by Dr. Lajos Pusztai, Professor of Medicine (Medical Oncology) at Yale Cancer Center, researchers across various institutions, and on behalf of the I-SPY consortium, developed a novel continuous residual cancer based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in preoperative breast cancer trials.